Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Am J Trop Med Hyg ; 104(5): 1851-1857, 2021 03 08.
Article in English | MEDLINE | ID: mdl-33684066

ABSTRACT

The price of certain antiparasitic drugs (e.g., albendazole and mebendazole) has dramatically increased since 2010. The effect of these rising prices on treatment costs and use of standard of care (SOC) drugs is unknown. To measure the impact of drug prices on overall outpatient cost and quality of care, we identified outpatient visits associated with ascariasis, hookworm, and trichuriasis infections from the 2010 to 2017 MarketScan Commercial Claims and Encounters and Multi-state Medicaid databases using Truven Health MarketScan Treatment Pathways. Evaluation was limited to members with continuous enrollment in non-capitated plans 30 days prior, and 90 days following, the first diagnosis. The utilization of SOC prescriptions was considered a marker for quality of care. The impact of drug price on the outpatient expenses was measured by comparing the changes in drug and nondrug outpatient payments per patient through Welch's two sample t-tests. The total outpatient payments per patient (drug and nondrug), for the three parasitic infections, increased between 2010 and 2017. The increase was driven primarily by prescription drug payments, which increased 20.6-137.0 times, as compared with nondrug outpatient payments, which increased 0.3-2.2 times. As prices of mebendazole and albendazole increased, a shift to alternative SOC and non-SOC drug utilization was observed. Using parasitic infection treatment as a model, increases in prescription drug prices can act as the primary driver of increasing outpatient care costs. Simultaneously, there was a shift to alternative SOC, but also to non-SOC drug treatment, suggesting a decrease in quality of care.


Subject(s)
Albendazole/economics , Anthelmintics/economics , Ascariasis/economics , Hookworm Infections/economics , Ivermectin/economics , Mebendazole/economics , Trichuriasis/economics , Albendazole/therapeutic use , Animals , Anthelmintics/therapeutic use , Ascariasis/diagnosis , Ascariasis/drug therapy , Ascariasis/parasitology , Drug Costs/trends , Health Expenditures/statistics & numerical data , Hookworm Infections/diagnosis , Hookworm Infections/drug therapy , Hookworm Infections/parasitology , Humans , Ivermectin/therapeutic use , Mebendazole/therapeutic use , Outpatients , Soil/parasitology , Standard of Care/trends , Trichuriasis/diagnosis , Trichuriasis/drug therapy , Trichuriasis/parasitology , United States
2.
PLoS Negl Trop Dis ; 10(8): e0004910, 2016 08.
Article in English | MEDLINE | ID: mdl-27509077

ABSTRACT

BACKGROUND: Many U.S.-bound refugees travel from countries where intestinal parasites (hookworm, Trichuris trichuria, Ascaris lumbricoides, and Strongyloides stercoralis) are endemic. These infections are rare in the United States and may be underdiagnosed or misdiagnosed, leading to potentially serious consequences. This evaluation examined the costs and benefits of combinations of overseas presumptive treatment of parasitic diseases vs. domestic screening/treating vs. no program. METHODS: An economic decision tree model terminating in Markov processes was developed to estimate the cost and health impacts of four interventions on an annual cohort of 27,700 U.S.-bound Asian refugees: 1) "No Program," 2) U.S. "Domestic Screening and Treatment," 3) "Overseas Albendazole and Ivermectin" presumptive treatment, and 4) "Overseas Albendazole and Domestic Screening for Strongyloides". Markov transition state models were used to estimate long-term effects of parasitic infections. Health outcome measures (four parasites) included outpatient cases, hospitalizations, deaths, life years, and quality-adjusted life years (QALYs). RESULTS: The "No Program" option is the least expensive ($165,923 per cohort) and least effective option (145 outpatient cases, 4.0 hospitalizations, and 0.67 deaths discounted over a 60-year period for a one-year cohort). The "Overseas Albendazole and Ivermectin" option ($418,824) is less expensive than "Domestic Screening and Treatment" ($3,832,572) or "Overseas Albendazole and Domestic Screening for Strongyloides" ($2,182,483). According to the model outcomes, the most effective treatment option is "Overseas Albendazole and Ivermectin," which reduces outpatient cases, deaths and hospitalization by around 80% at an estimated net cost of $458,718 per death averted, or $2,219/$24,036 per QALY/life year gained relative to "No Program". DISCUSSION: Overseas presumptive treatment for U.S.-bound refugees is a cost-effective intervention that is less expensive and at least as effective as domestic screening and treatment programs. The addition of ivermectin to albendazole reduces the prevalence of chronic strongyloidiasis and the probability of rare, but potentially fatal, disseminated strongyloidiasis.


Subject(s)
Helminthiasis/drug therapy , Helminthiasis/economics , Intestinal Diseases, Parasitic/drug therapy , Intestinal Diseases, Parasitic/economics , Mass Screening/economics , Refugees , Ancylostomatoidea/isolation & purification , Animals , Ascariasis/diagnosis , Ascariasis/drug therapy , Ascariasis/economics , Ascariasis/epidemiology , Ascaris lumbricoides/isolation & purification , Asia/epidemiology , Cost-Benefit Analysis , Early Medical Intervention/economics , Helminthiasis/diagnostic imaging , Helminthiasis/epidemiology , Hookworm Infections/diagnosis , Hookworm Infections/drug therapy , Hookworm Infections/economics , Hookworm Infections/epidemiology , Hospitalization/economics , Hospitalization/statistics & numerical data , Humans , Intestinal Diseases, Parasitic/diagnostic imaging , Intestinal Diseases, Parasitic/epidemiology , Models, Economic , Prevalence , Strongyloides stercoralis/isolation & purification , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Strongyloidiasis/economics , Strongyloidiasis/epidemiology , Trichuriasis/diagnosis , Trichuriasis/drug therapy , Trichuriasis/economics , Trichuriasis/epidemiology , Trichuris/isolation & purification , United States/epidemiology
4.
Trop Med Int Health ; 6(6): 449-57, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11422959

ABSTRACT

We conducted a randomized clinical intervention trial over 24 weeks on a tea estate in north-east Bangladesh to investigate the effect of iron supplementation and anthelmintic treatment on the labour productivity of adult female tea pluckers. A total of 553 full-time tea pluckers, not pregnant and not breastfeeding, were randomly assigned to one of the four intervention groups: group 1 received iron supplementation on a weekly basis, group 2 received anthelmintic treatment at the beginning and half-way through the trial (week 12), group 3 received both iron supplementation as group 1 and anthelmintic treatment as group 2, and group 4 was a control group and received placebos. No significant difference in labour productivity was found between the four intervention groups over the trial period. However, there was a negative association for all three worms (Ascaris lumbricoides, Trichuris trichiura and hookworms) between the intensity of helminth infections (eggs/g faeces) and all measures of labour productivity. Lower haemoglobin values and anaemia (< 120 g/l Hb) were both associated with lower labour productivity and more days sick and absent. Taller women with greater arm circumference were able to pluck more green leaves, earn higher wages and were absent less often.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Anthelmintics/therapeutic use , Efficiency , Ferrous Compounds/therapeutic use , Helminthiasis/drug therapy , Adolescent , Adult , Aged , Agriculture , Albendazole/therapeutic use , Anemia, Iron-Deficiency/economics , Anemia, Iron-Deficiency/parasitology , Ascariasis/complications , Ascariasis/drug therapy , Ascariasis/economics , Bangladesh/epidemiology , Dietary Supplements , Drug Therapy, Combination , Female , Folic Acid/therapeutic use , Helminthiasis/complications , Helminthiasis/economics , Hookworm Infections/complications , Hookworm Infections/drug therapy , Hookworm Infections/economics , Humans , Income , Middle Aged , Nutritional Status , Sick Leave/statistics & numerical data , Tea , Trichuriasis/complications , Trichuriasis/drug therapy , Trichuriasis/economics
5.
J Parasitol ; 85(1): 6-11, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10207355

ABSTRACT

The study examined the cost effectiveness of 4 different regimens in reducing the prevalence and intensity of infection of Ascaris lumbricoides, Trichuris trichiura, and hookworm over an 18-mo period in randomized community samples of children aged 2-8 yr living in rural Bangladesh. The household was the unit of randomization in each community. The 4 regimens were (1) only chemotherapy to all household members at the commencement of the study (i.e., at an interval of 18 mo), (2) same as group (1) and regular health education throughout the study period, (3) chemotherapy to all household members at the commencement of the study and subsequent chemotherapy to all children at intervals of 6 mo, and (4) same as group 3 with the addition of regular health education throughout the study period. Health education (through home and school visits and focus group discussions) was aimed at increasing awareness of worm transmission and the disabilities caused by intestinal helminths. Simple ways of improving personal hygiene and sanitation through hand washing, nail trimming, wearing of shoes, and use of a latrine and clean water supplies were encouraged. Because albendazole is a broad spectrum anthelmintic, the cost effectiveness of the 4 interventions were compared by the weighted percentage reduction in prevalence and the weighted percentage reduction in intensities of infection as measured by geometric mean egg loads of all 3 worms combined. The most cost-effective strategy was the single albendazole mass chemotherapy at an interval of 18 mo. The 2 regimens involving health education were the least cost effective.


Subject(s)
Albendazole/therapeutic use , Anthelmintics/therapeutic use , Intestinal Diseases, Parasitic/prevention & control , Patient Education as Topic/economics , Albendazole/economics , Animals , Anthelmintics/economics , Ascariasis/economics , Ascariasis/epidemiology , Ascariasis/prevention & control , Bangladesh/epidemiology , Child , Child, Preschool , Cost-Benefit Analysis , Feces/parasitology , Hookworm Infections/economics , Hookworm Infections/epidemiology , Hookworm Infections/prevention & control , Humans , Intestinal Diseases, Parasitic/economics , Intestinal Diseases, Parasitic/epidemiology , Parasite Egg Count , Prevalence , Rural Population , Trichuriasis/economics , Trichuriasis/epidemiology , Trichuriasis/prevention & control
6.
Rev. cuba. med. trop ; 45(3): 180-3, sept.-dic. 1993. tab
Article in Spanish | LILACS | ID: lil-158477

ABSTRACT

Se estudió un grupo de 18 personas predispuestas a infectarse con Trichuris trichiura, cada uno fue pareado en sexo, edad, aspecto externo de la vivienda y zona de residencia con 2 personas no predispuestas que constituyeron el grupo control para determinar qué aspectos sociales y psicológicos se asocian con la predisposición a la tricuriasis. Se encontró que los sujetos predispuestos de la muestra estudiada tienen hábitos higiénicos deficientes, viven hacinados, con un ingreso percápita inferior a $ 49,00; además presentan deficiencias en el rendimiento intelectual


Subject(s)
Humans , Housing , Sex , Socioeconomic Factors , Trichuriasis/economics
7.
J Anim Sci ; 66(6): 1548-54, 1988 Jun.
Article in English | MEDLINE | ID: mdl-2969380

ABSTRACT

Experimental infections of pigs with Strongyloides ransomi, Stephanurus dentatus, Ascaris suum, Oesophagostomum spp. or Trichuris suis at increasing levels generally decrease daily gain and increase feed to gain ratio linearly. At lower, subclinical levels of infection, the feed to gain ratio typically is increased 3% to 6% by an infection. Based on low-level experimental infections with A. suum, the economic loss to producers in the U.S. from increased feed to gain ratio is estimated at $155 million annually.


Subject(s)
Body Weight , Nematode Infections/veterinary , Swine Diseases/parasitology , Swine/growth & development , Animals , Ascariasis/economics , Ascariasis/epidemiology , Ascariasis/veterinary , Nematode Infections/economics , Nematode Infections/epidemiology , Oesophagostomiasis/economics , Oesophagostomiasis/epidemiology , Oesophagostomiasis/veterinary , Strongylida Infections/economics , Strongylida Infections/epidemiology , Strongylida Infections/veterinary , Strongyloidiasis/economics , Strongyloidiasis/epidemiology , Strongyloidiasis/veterinary , Swine Diseases/economics , Swine Diseases/epidemiology , Trichuriasis/economics , Trichuriasis/epidemiology , Trichuriasis/veterinary , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...